Ratings Luye Pharma Group Ltd.

Equities

Market Closed - Hong Kong S.E. Other stock markets 09:08:05 13/09/2024 BST			5-day change	1st Jan Change
2.950 ^HKD	+0.68%		-3.28%	-20.91%

08-30	Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4	MT
08-28	Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company appears to be poorly valued given its net asset value.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The company's earnings releases usually do not meet expectations.

Source: Surperformance

Source: Refinitiv

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	LUYE PHARMA GROUP LTD.				1.42B
	ELI LILLY AND COMPANY				832B
	NOVO NORDISK A/S				605B
	JOHNSON & JOHNSON				398B
	ABBVIE INC.				343B
	MERCK & CO., INC.				294B
	ROCHE HOLDING AG				252B
	ASTRAZENECA PLC				243B
	NOVARTIS AG				234B
	AMGEN INC.				179B
	Average				338.15B
	Weighted average by Cap.